CD276 and breast cancer: Previous studies have demonstrated that B7-H3/CD276 primarily exerted a co-inhibitory function in tumor immunity and was overexpressed in various malignancies, including NSCLC and breast cancer, where it was closely associated with immune evasion by tumor cells [78–82].